Dupixent® (dupilumab) is now approved in India for the treatment of adults with moderate-to-severe atopic dermatitis
Mumbai, 12th July 2023. Sanofi Healthcare India Pvt. Ltd. today announced that it has received marketing authorization for Dupixent® (dupilumab),…